Recently, we could identify DNA methylation of the immune checkpoint tumor necrosis factor receptor super family member 9 (4-1BB, TNFRSF9) as a predictive biomarker for response to immunotherapy in melanoma patients [47]. Here, TNFRSF9 is linked to melanoma.